ArticleDrug delivery and translational research2020
Zein-based nanoparticles for the oral delivery of insulin.
Article in Drug delivery and translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Nanoparticle and microparticle-based systems for enhanced oral insulin delivery: A systematic review and meta-analysis.Journal of nanobiotechnology · 2024Pooled it
- Re-engineering insulin for oral delivery: structural modifications, advanced formulation strategies, and future directions.Drug delivery · 2026Review
- Albumin-based nanocarriers: Singularities, synthesis methods, clinical relevance and targeting strategies in cancer.Acta pharmaceutica Sinica. B · 2026Review
- Development of EL/PLGA nanoparticles for oral delivery of methotrexate with enhanced bioavailability and reduced toxicity.Drug delivery and translational research · 2026Article
- From Synthesis to Therapeutics: Bioactive-Coated Zein Nanoparticles in Drug Delivery.Biopolymers · 2026Review
- Development and Characterization of Zein/Eudragit Composite Nanoparticles for Insulin Intranasal Delivery.ACS omega · 2025Article
- Microneedle Innovations in Oral Therapeutics: Transforming Protein and Peptide Delivery.AAPS PharmSciTech · 2025Review
- Exploring the potential of polymers: advancements in oral nanocarrier technology.Beilstein journal of nanotechnology · 2025Review
- Revolutionizing Cancer Treatment: The Promising Horizon of Zein Nanosystems.ACS biomaterials science & engineering · 2024Review
- Polymeric nanoparticles (PNPs) for oral delivery of insulin.Journal of nanobiotechnology · 2024Review
- Zein nanoparticles as oral carrier for mometasone furoate delivery.Drug delivery and translational research · 2023Article
- Functionalized zein nanoparticles targeting neonatal Fc receptor to enhance lung absorption of peptides.Drug delivery and translational research · 2023Article
- Review
- Nanomedical research and development in Spain: improving the treatment of diseases from the nanoscale.Frontiers in bioengineering and biotechnology · 2023Review
- Formulation, Characterisation and Evaluation of the Antihypertensive Peptides, Isoleucine-Proline-Proline and Leucine-Lysine-Proline in Chitosan Nanoparticles Coated with Zein for Oral Drug Delivery.International journal of molecular sciences · 2022Article
- Arabinoxylans-Based Oral Insulin Delivery System Targeting the Colon: Simulation in a Human Intestinal Microbial Ecosystem and Evaluation in Diabetic Rats.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Review
- Preparation, Characteristics, and Advantages of Plant Protein-Based Bioactive Molecule Delivery Systems.Foods (Basel, Switzerland) · 2022Review
- Zein-Based Nanoparticles as Oral Carriers for Insulin Delivery.Pharmaceutics · 2021Article
- Surface-Tailored Zein Nanoparticles: Strategies and Applications.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The aim of this work was to evaluate oral nanocarriers, prepared from zein nanoparticles coated with a poly(anhydride)-thiamine conjugate (GT), for the delivery of insulin. Nanoparticles displayed a size of 250 nm with a negative surface charge, and an insulin loading of 80 μg/mg. Under simulated gastric conditions, GT-coated nanoparticles released a significantly lower amount of insulin than bare ones; whereas in simulated intestinal conditions, both types of nanoparticles displayed a similar behavior. The effect of insulin on the lipid metabolism of C. elegans under high glucose conditions, characterized by a reduction of the fat content, was also investigated. The effect was significantly higher for the nanoencapsulated forms of insulin than for the free protein (p < 0.001). This effect was two times higher for GT-coated nanoparticles than for bare ones. In rats, the hypoglycemic effect and the pharmacokinetic profile of insulin-loaded nanoparticles orally administered (50 IU/kg) were evaluated. The glycemia of animals slowly decreased reaching a minimum 6-10-h post-administration, with a maximum decrease of about 60%. The pharmacological availability of nanoencapsulated insulin was 13.5%. In serum, nanoparticles provided a maximum of insulin 4-h post-administration, and its relative oral bioavailability was 5.2% (compared with a sc formulation of insulin). Graphical abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.